ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org181, 30 Jun 2025 07:06:67 +00:00181, 30 Jun 2025 07:06:67 +00:00 Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations https://www.esmo.orgnull<p>Findings from the VERITAC-2 study</p>noreply@esmo.orgb951eb62-bb97-4923-8181-562391b74606Mon, 30 Jun 2025 07:06:00 +00:00 FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ARANOTE study</p>noreply@esmo.org71cae980-92df-4341-aad8-72119afb49c6Fri, 27 Jun 2025 07:06:00 +00:00 EMA Recommends Granting a Marketing Authorisation for Inavolisib https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with <em>PIK3CA</em>-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer</p>noreply@esmo.org26ed0eb1-6cad-4120-ac54-484b3575cd0fThu, 26 Jun 2025 07:06:00 +00:00 Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC https://www.esmo.orgnull<p>Findings from the BREAKWATER study</p>noreply@esmo.orgc7233b12-26fd-4902-adbe-b539a861667aWed, 25 Jun 2025 07:06:00 +00:00 ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July https://www.esmo.orgnull<p>The ESMO Gastrointestinal Cancers Congress 2025 will take place between 2-5 July in Barcelona, bringing together leading experts to present new data, share insights, and discuss recent development in the understanding and treatment of gastrointestinal malignancies</p>noreply@esmo.orgfdf17ac1-7308-4062-a6e7-d388d21a4389Wed, 25 Jun 2025 06:06:00 +00:00 Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone https://www.esmo.orgnull<p>Findings from the CheckMate 816 study</p>noreply@esmo.org2441830b-ee0f-4bce-b4d7-5f239d388b1dTue, 24 Jun 2025 07:06:00 +00:00 ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer https://www.esmo.orgnull<p>In March 2025, ESMO participated in a consultation on the European Economic and Social Committee (EESC) own-initiative opinion regarding the New Action Plan to implement the European Pillar of Social Rights (EPSR)</p>noreply@esmo.org2411b658-ffcd-4d83-987d-ac93788fca92Mon, 23 Jun 2025 13:06:00 +00:00 Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ROSELLA study</p>noreply@esmo.org75324d67-5154-4f59-ae40-7cc3916e23bdMon, 23 Jun 2025 07:06:00 +00:00 FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies</p>noreply@esmo.org7cc3533d-efcb-414b-beab-f974542cec23Fri, 20 Jun 2025 08:06:00 +00:00 EMA Recommends Extension of Therapeutic Indications for Acalabrutinib https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax</p>noreply@esmo.orgb6a9b38b-32b5-44d2-82e1-27de189d137aWed, 18 Jun 2025 08:06:00 +00:00 Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma https://www.esmo.orgnull<p>Findings from the C-POST study</p>noreply@esmo.orga082d1b4-6664-4eb6-9a9f-58df174a0c43Wed, 18 Jun 2025 08:06:00 +00:00 French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research https://www.esmo.orgnull<p>Brussels, 12 June 2025 – The French Senate’s Committee on European Affairs has adopted a political opinion urging the European Commission to revise Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), aligning with ESMO’s concerns regarding the regulation’s impact on oncological research</p>noreply@esmo.orga9ca2d68-adcf-4143-b95a-35d1f35dedb3Tue, 17 Jun 2025 09:06:00 +00:00 Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS https://www.esmo.orgnull<p>Findings from the CO.21 CHALLENGE study</p>noreply@esmo.org9b8fa214-d4d6-488b-b4e1-c192e19006e2Tue, 17 Jun 2025 07:06:00 +00:00 Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy https://www.esmo.orgnull<p>Findings from the DeLLphi-304 study</p>noreply@esmo.org4a4568b6-63e1-4e02-8853-c2aa4b45ceebMon, 16 Jun 2025 07:06:00 +00:00 ESMO Announces Results of 2025 Elections https://www.esmo.orgnull<p>ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.</p>noreply@esmo.org819c8a73-761d-430c-b718-4bd1bfa7197bSat, 14 Jun 2025 07:06:00 +00:00 FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LUMINOSITY study</p>noreply@esmo.orgee2d6847-9b0d-430e-8990-6d9ffdec1940Fri, 13 Jun 2025 07:06:00 +00:00 EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CD30-positive Stage IIB with risk factors, Stage III or Stage IV Hodgkin lymphoma, in combination with BrECADD regimen</p>noreply@esmo.orgbed007cb-ddc9-4908-8218-bcd5b48e5156Thu, 12 Jun 2025 07:06:00 +00:00 ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act https://www.esmo.orgnull<p>Ensuring equitable access to cancer treatments remains central to EU health security efforts</p>noreply@esmo.org1497f5d0-81f4-498c-872d-7c57a4279aafWed, 11 Jun 2025 09:06:00 +00:00 Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer https://www.esmo.orgnull<p>Findings from the OASIS-4 study</p>noreply@esmo.org7e4e30aa-f7b2-414e-ba76-24f502d9980dWed, 11 Jun 2025 07:06:00 +00:00 ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer https://www.esmo.orgnull<p>Delivering the right EU policies to support the biotechnology sector holds enormous potential to enhance drug discovery in oncology, enable more targeted and precise cancer therapies, and support personalised medicine.</p>noreply@esmo.org12ff9c83-60ce-49cb-a21f-979904608b6aTue, 10 Jun 2025 22:06:00 +00:00 ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org181, 30 Jun 2025 07:06:26 +00:00181, 30 Jun 2025 07:06:26 +00:00 Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations https://www.esmo.orgnull<p>Findings from the VERITAC-2 study</p>noreply@esmo.orgb951eb62-bb97-4923-8181-562391b74606Mon, 30 Jun 2025 07:06:00 +00:00 FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ARANOTE study</p>noreply@esmo.org71cae980-92df-4341-aad8-72119afb49c6Fri, 27 Jun 2025 07:06:00 +00:00 EMA Recommends Granting a Marketing Authorisation for Inavolisib https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with <em>PIK3CA</em>-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer</p>noreply@esmo.org26ed0eb1-6cad-4120-ac54-484b3575cd0fThu, 26 Jun 2025 07:06:00 +00:00 Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC https://www.esmo.orgnull<p>Findings from the BREAKWATER study</p>noreply@esmo.orgc7233b12-26fd-4902-adbe-b539a861667aWed, 25 Jun 2025 07:06:00 +00:00 ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July https://www.esmo.orgnull<p>The ESMO Gastrointestinal Cancers Congress 2025 will take place between 2-5 July in Barcelona, bringing together leading experts to present new data, share insights, and discuss recent development in the understanding and treatment of gastrointestinal malignancies</p>noreply@esmo.orgfdf17ac1-7308-4062-a6e7-d388d21a4389Wed, 25 Jun 2025 06:06:00 +00:00 Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone https://www.esmo.orgnull<p>Findings from the CheckMate 816 study</p>noreply@esmo.org2441830b-ee0f-4bce-b4d7-5f239d388b1dTue, 24 Jun 2025 07:06:00 +00:00 ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer https://www.esmo.orgnull<p>In March 2025, ESMO participated in a consultation on the European Economic and Social Committee (EESC) own-initiative opinion regarding the New Action Plan to implement the European Pillar of Social Rights (EPSR)</p>noreply@esmo.org2411b658-ffcd-4d83-987d-ac93788fca92Mon, 23 Jun 2025 13:06:00 +00:00 Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ROSELLA study</p>noreply@esmo.org75324d67-5154-4f59-ae40-7cc3916e23bdMon, 23 Jun 2025 07:06:00 +00:00 FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies</p>noreply@esmo.org7cc3533d-efcb-414b-beab-f974542cec23Fri, 20 Jun 2025 08:06:00 +00:00 EMA Recommends Extension of Therapeutic Indications for Acalabrutinib https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax</p>noreply@esmo.orgb6a9b38b-32b5-44d2-82e1-27de189d137aWed, 18 Jun 2025 08:06:00 +00:00 Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma https://www.esmo.orgnull<p>Findings from the C-POST study</p>noreply@esmo.orga082d1b4-6664-4eb6-9a9f-58df174a0c43Wed, 18 Jun 2025 08:06:00 +00:00 French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research https://www.esmo.orgnull<p>Brussels, 12 June 2025 – The French Senate’s Committee on European Affairs has adopted a political opinion urging the European Commission to revise Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), aligning with ESMO’s concerns regarding the regulation’s impact on oncological research</p>noreply@esmo.orga9ca2d68-adcf-4143-b95a-35d1f35dedb3Tue, 17 Jun 2025 09:06:00 +00:00 Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS https://www.esmo.orgnull<p>Findings from the CO.21 CHALLENGE study</p>noreply@esmo.org9b8fa214-d4d6-488b-b4e1-c192e19006e2Tue, 17 Jun 2025 07:06:00 +00:00 Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy https://www.esmo.orgnull<p>Findings from the DeLLphi-304 study</p>noreply@esmo.org4a4568b6-63e1-4e02-8853-c2aa4b45ceebMon, 16 Jun 2025 07:06:00 +00:00 ESMO Announces Results of 2025 Elections https://www.esmo.orgnull<p>ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.</p>noreply@esmo.org819c8a73-761d-430c-b718-4bd1bfa7197bSat, 14 Jun 2025 07:06:00 +00:00 FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LUMINOSITY study</p>noreply@esmo.orgee2d6847-9b0d-430e-8990-6d9ffdec1940Fri, 13 Jun 2025 07:06:00 +00:00 EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CD30-positive Stage IIB with risk factors, Stage III or Stage IV Hodgkin lymphoma, in combination with BrECADD regimen</p>noreply@esmo.orgbed007cb-ddc9-4908-8218-bcd5b48e5156Thu, 12 Jun 2025 07:06:00 +00:00 ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act https://www.esmo.orgnull<p>Ensuring equitable access to cancer treatments remains central to EU health security efforts</p>noreply@esmo.org1497f5d0-81f4-498c-872d-7c57a4279aafWed, 11 Jun 2025 09:06:00 +00:00 Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer https://www.esmo.orgnull<p>Findings from the OASIS-4 study</p>noreply@esmo.org7e4e30aa-f7b2-414e-ba76-24f502d9980dWed, 11 Jun 2025 07:06:00 +00:00 ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer https://www.esmo.orgnull<p>Delivering the right EU policies to support the biotechnology sector holds enormous potential to enhance drug discovery in oncology, enable more targeted and precise cancer therapies, and support personalised medicine.</p>noreply@esmo.org12ff9c83-60ce-49cb-a21f-979904608b6aTue, 10 Jun 2025 22:06:00 +00:00 ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org181, 30 Jun 2025 07:06:45 +00:00181, 30 Jun 2025 07:06:45 +00:00 Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations https://www.esmo.orgnull<p>Findings from the VERITAC-2 study</p>noreply@esmo.orgb951eb62-bb97-4923-8181-562391b74606Mon, 30 Jun 2025 07:06:00 +00:00 FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ARANOTE study</p>noreply@esmo.org71cae980-92df-4341-aad8-72119afb49c6Fri, 27 Jun 2025 07:06:00 +00:00 EMA Recommends Granting a Marketing Authorisation for Inavolisib https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with <em>PIK3CA</em>-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer</p>noreply@esmo.org26ed0eb1-6cad-4120-ac54-484b3575cd0fThu, 26 Jun 2025 07:06:00 +00:00 Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC https://www.esmo.orgnull<p>Findings from the BREAKWATER study</p>noreply@esmo.orgc7233b12-26fd-4902-adbe-b539a861667aWed, 25 Jun 2025 07:06:00 +00:00 ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July https://www.esmo.orgnull<p>The ESMO Gastrointestinal Cancers Congress 2025 will take place between 2-5 July in Barcelona, bringing together leading experts to present new data, share insights, and discuss recent development in the understanding and treatment of gastrointestinal malignancies</p>noreply@esmo.orgfdf17ac1-7308-4062-a6e7-d388d21a4389Wed, 25 Jun 2025 06:06:00 +00:00 Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone https://www.esmo.orgnull<p>Findings from the CheckMate 816 study</p>noreply@esmo.org2441830b-ee0f-4bce-b4d7-5f239d388b1dTue, 24 Jun 2025 07:06:00 +00:00 ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer https://www.esmo.orgnull<p>In March 2025, ESMO participated in a consultation on the European Economic and Social Committee (EESC) own-initiative opinion regarding the New Action Plan to implement the European Pillar of Social Rights (EPSR)</p>noreply@esmo.org2411b658-ffcd-4d83-987d-ac93788fca92Mon, 23 Jun 2025 13:06:00 +00:00 Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ROSELLA study</p>noreply@esmo.org75324d67-5154-4f59-ae40-7cc3916e23bdMon, 23 Jun 2025 07:06:00 +00:00 FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies</p>noreply@esmo.org7cc3533d-efcb-414b-beab-f974542cec23Fri, 20 Jun 2025 08:06:00 +00:00 EMA Recommends Extension of Therapeutic Indications for Acalabrutinib https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax</p>noreply@esmo.orgb6a9b38b-32b5-44d2-82e1-27de189d137aWed, 18 Jun 2025 08:06:00 +00:00 Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma https://www.esmo.orgnull<p>Findings from the C-POST study</p>noreply@esmo.orga082d1b4-6664-4eb6-9a9f-58df174a0c43Wed, 18 Jun 2025 08:06:00 +00:00 French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research https://www.esmo.orgnull<p>Brussels, 12 June 2025 – The French Senate’s Committee on European Affairs has adopted a political opinion urging the European Commission to revise Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), aligning with ESMO’s concerns regarding the regulation’s impact on oncological research</p>noreply@esmo.orga9ca2d68-adcf-4143-b95a-35d1f35dedb3Tue, 17 Jun 2025 09:06:00 +00:00 Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS https://www.esmo.orgnull<p>Findings from the CO.21 CHALLENGE study</p>noreply@esmo.org9b8fa214-d4d6-488b-b4e1-c192e19006e2Tue, 17 Jun 2025 07:06:00 +00:00 Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy https://www.esmo.orgnull<p>Findings from the DeLLphi-304 study</p>noreply@esmo.org4a4568b6-63e1-4e02-8853-c2aa4b45ceebMon, 16 Jun 2025 07:06:00 +00:00 ESMO Announces Results of 2025 Elections https://www.esmo.orgnull<p>ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.</p>noreply@esmo.org819c8a73-761d-430c-b718-4bd1bfa7197bSat, 14 Jun 2025 07:06:00 +00:00 FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LUMINOSITY study</p>noreply@esmo.orgee2d6847-9b0d-430e-8990-6d9ffdec1940Fri, 13 Jun 2025 07:06:00 +00:00 EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CD30-positive Stage IIB with risk factors, Stage III or Stage IV Hodgkin lymphoma, in combination with BrECADD regimen</p>noreply@esmo.orgbed007cb-ddc9-4908-8218-bcd5b48e5156Thu, 12 Jun 2025 07:06:00 +00:00 ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act https://www.esmo.orgnull<p>Ensuring equitable access to cancer treatments remains central to EU health security efforts</p>noreply@esmo.org1497f5d0-81f4-498c-872d-7c57a4279aafWed, 11 Jun 2025 09:06:00 +00:00 Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer https://www.esmo.orgnull<p>Findings from the OASIS-4 study</p>noreply@esmo.org7e4e30aa-f7b2-414e-ba76-24f502d9980dWed, 11 Jun 2025 07:06:00 +00:00 ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer https://www.esmo.orgnull<p>Delivering the right EU policies to support the biotechnology sector holds enormous potential to enhance drug discovery in oncology, enable more targeted and precise cancer therapies, and support personalised medicine.</p>noreply@esmo.org12ff9c83-60ce-49cb-a21f-979904608b6aTue, 10 Jun 2025 22:06:00 +00:00 ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org181, 30 Jun 2025 07:06:70 +00:00181, 30 Jun 2025 07:06:70 +00:00 Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations https://www.esmo.orgnull<p>Findings from the VERITAC-2 study</p>noreply@esmo.orgb951eb62-bb97-4923-8181-562391b74606Mon, 30 Jun 2025 07:06:00 +00:00 FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ARANOTE study</p>noreply@esmo.org71cae980-92df-4341-aad8-72119afb49c6Fri, 27 Jun 2025 07:06:00 +00:00 EMA Recommends Granting a Marketing Authorisation for Inavolisib https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with <em>PIK3CA</em>-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer</p>noreply@esmo.org26ed0eb1-6cad-4120-ac54-484b3575cd0fThu, 26 Jun 2025 07:06:00 +00:00 Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC https://www.esmo.orgnull<p>Findings from the BREAKWATER study</p>noreply@esmo.orgc7233b12-26fd-4902-adbe-b539a861667aWed, 25 Jun 2025 07:06:00 +00:00 ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July https://www.esmo.orgnull<p>The ESMO Gastrointestinal Cancers Congress 2025 will take place between 2-5 July in Barcelona, bringing together leading experts to present new data, share insights, and discuss recent development in the understanding and treatment of gastrointestinal malignancies</p>noreply@esmo.orgfdf17ac1-7308-4062-a6e7-d388d21a4389Wed, 25 Jun 2025 06:06:00 +00:00 Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone https://www.esmo.orgnull<p>Findings from the CheckMate 816 study</p>noreply@esmo.org2441830b-ee0f-4bce-b4d7-5f239d388b1dTue, 24 Jun 2025 07:06:00 +00:00 ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer https://www.esmo.orgnull<p>In March 2025, ESMO participated in a consultation on the European Economic and Social Committee (EESC) own-initiative opinion regarding the New Action Plan to implement the European Pillar of Social Rights (EPSR)</p>noreply@esmo.org2411b658-ffcd-4d83-987d-ac93788fca92Mon, 23 Jun 2025 13:06:00 +00:00 Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ROSELLA study</p>noreply@esmo.org75324d67-5154-4f59-ae40-7cc3916e23bdMon, 23 Jun 2025 07:06:00 +00:00 FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies</p>noreply@esmo.org7cc3533d-efcb-414b-beab-f974542cec23Fri, 20 Jun 2025 08:06:00 +00:00 EMA Recommends Extension of Therapeutic Indications for Acalabrutinib https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax</p>noreply@esmo.orgb6a9b38b-32b5-44d2-82e1-27de189d137aWed, 18 Jun 2025 08:06:00 +00:00 Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma https://www.esmo.orgnull<p>Findings from the C-POST study</p>noreply@esmo.orga082d1b4-6664-4eb6-9a9f-58df174a0c43Wed, 18 Jun 2025 08:06:00 +00:00 French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research https://www.esmo.orgnull<p>Brussels, 12 June 2025 – The French Senate’s Committee on European Affairs has adopted a political opinion urging the European Commission to revise Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), aligning with ESMO’s concerns regarding the regulation’s impact on oncological research</p>noreply@esmo.orga9ca2d68-adcf-4143-b95a-35d1f35dedb3Tue, 17 Jun 2025 09:06:00 +00:00 Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS https://www.esmo.orgnull<p>Findings from the CO.21 CHALLENGE study</p>noreply@esmo.org9b8fa214-d4d6-488b-b4e1-c192e19006e2Tue, 17 Jun 2025 07:06:00 +00:00 Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy https://www.esmo.orgnull<p>Findings from the DeLLphi-304 study</p>noreply@esmo.org4a4568b6-63e1-4e02-8853-c2aa4b45ceebMon, 16 Jun 2025 07:06:00 +00:00 ESMO Announces Results of 2025 Elections https://www.esmo.orgnull<p>ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.</p>noreply@esmo.org819c8a73-761d-430c-b718-4bd1bfa7197bSat, 14 Jun 2025 07:06:00 +00:00 FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LUMINOSITY study</p>noreply@esmo.orgee2d6847-9b0d-430e-8990-6d9ffdec1940Fri, 13 Jun 2025 07:06:00 +00:00 EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CD30-positive Stage IIB with risk factors, Stage III or Stage IV Hodgkin lymphoma, in combination with BrECADD regimen</p>noreply@esmo.orgbed007cb-ddc9-4908-8218-bcd5b48e5156Thu, 12 Jun 2025 07:06:00 +00:00 ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act https://www.esmo.orgnull<p>Ensuring equitable access to cancer treatments remains central to EU health security efforts</p>noreply@esmo.org1497f5d0-81f4-498c-872d-7c57a4279aafWed, 11 Jun 2025 09:06:00 +00:00 Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer https://www.esmo.orgnull<p>Findings from the OASIS-4 study</p>noreply@esmo.org7e4e30aa-f7b2-414e-ba76-24f502d9980dWed, 11 Jun 2025 07:06:00 +00:00 ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer https://www.esmo.orgnull<p>Delivering the right EU policies to support the biotechnology sector holds enormous potential to enhance drug discovery in oncology, enable more targeted and precise cancer therapies, and support personalised medicine.</p>noreply@esmo.org12ff9c83-60ce-49cb-a21f-979904608b6aTue, 10 Jun 2025 22:06:00 +00:00